Genentech reports Phase III CELESTIMO PFS improvement for Lunsumio
Genentech says its Phase III CELESTIMO study of Lunsumio (mosunetuzumab-axgb) plus lenalidomide vs Rituxan (rituximab) plus lenalidomide in relapsed/refractory follicular lymphoma showed significantly improved progression-free survival.